Jake Strzelecki

Jake Strzelecki has a diverse work experience spanning over two decades. Jake started their career at Merck as a Project Manager in Engineering from 1997 to 2000. Jake then moved on to Genentech, where they worked as a Project Manager in CMC Portfolio Management from 2002 to 2004 and as a Senior Project Manager in Product Portfolio Management from 2004 to 2008.

Following their time at Genentech, Jake joined Biodesix, Inc. in 2009 as a Senior Manager in Strategic Marketing until 2011. Jake then transitioned to the role of Director in Business Development, where they established diagnostic collaboration agreements with bio-pharmaceutical companies and developed forecast and valuation models for partnering negotiations until 2014.

In 2014, Jake joined Medivation as an Associate Director in Portfolio Market Planning, supporting Xtandi market planning and sales in metastatic prostate cancer. Jake also contributed to commercial strategy analysis, market research, forecasting, and competitive strategy for various initiatives until 2017.

Jake's most recent experience includes working at Corcept Therapeutics since 2018. Jake began as an Associate Director in Pipeline & Portfolio Market Planning from 2018 to 2020. Jake then advanced to the role of Director in the same division from 2020 to 2022. Currently, they are serving as the Senior Director in Commercial Oncology, leading US launch planning for relacorilant in platinum-resistant ovarian cancer and overseeing the Commercial Oncology division on an interim basis.

Throughout their career, Jake has demonstrated strong leadership skills, successfully built teams, and provided strategic guidance in various therapeutic areas such as Cushing syndrome, oncology, psychiatry, NASH, and ALS.

Jake Strzelecki completed their Bachelor of Science degree in Chemical Engineering from Penn State University from 1992 to 1996. Following that, they pursued their Master of Business Administration (MBA) from Cornell Johnson Graduate School of Management from 2000 to 2002.